Published in J Biol Chem on February 27, 2002
Obesity as a major risk factor for cancer. J Obes (2013) 2.26
Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol (2006) 2.01
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell (2003) 1.65
Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer (2005) 1.64
MiR-223 suppresses cell proliferation by targeting IGF-1R. PLoS One (2011) 1.41
Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol (2003) 1.21
MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. PLoS One (2012) 1.20
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10
Analyzing serum-stimulated prostate cancer cell lines after low-fat, high-fiber diet and exercise intervention. Evid Based Complement Alternat Med (2011) 1.03
Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol (2008) 1.01
Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth. Cell Death Dis (2014) 0.99
Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene (2015) 0.93
A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol (2007) 0.92
Cholesterol Perturbation in Mice Results in p53 Degradation and Axonal Pathology through p38 MAPK and Mdm2 Activation. PLoS One (2010) 0.88
IGF-IR in neuroprotection and brain tumors. Front Biosci (Landmark Ed) (2009) 0.83
Estrogen receptor beta-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma. J Cell Physiol (2009) 0.82
Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One (2011) 0.79
p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells. Oncotarget (2016) 0.79
A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line. Int J Oncol (2014) 0.78
BMP9-Induced Survival Effect in Liver Tumor Cells Requires p38MAPK Activation. Int J Mol Sci (2015) 0.78
Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget (2016) 0.76
Insulin-like growth factor receptor-1 overexpression is associated with poor response of rectal cancers to radiotherapy. World J Gastroenterol (2014) 0.76
Effects of creatine monohydrate supplementation on exercise-induced apoptosis in athletes: A randomized, double-blind, and placebo-controlled study. J Res Med Sci (2015) 0.75
Ursolic Acid-Regulated Energy Metabolism-Reliever or Propeller of Ultraviolet-Induced Oxidative Stress and DNA Damage? Proteomes (2014) 0.75
Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals. Oncogene (2016) 0.75
Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection Pathways. Front Oncol (2016) 0.75
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med (2004) 2.51
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res (2010) 2.13
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes (2012) 1.86
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology (2006) 1.71
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer (2012) 1.48
The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev (2014) 1.45
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 1.44
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 1.44
The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.40
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes (2004) 1.36
Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res (2009) 1.35
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci (2011) 1.34
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol (2008) 1.33
Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am (2007) 1.29
Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology (2005) 1.29
Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 1.28
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28
PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene (2004) 1.27
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology (2009) 1.21
Targeted loss of GHR signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes (2012) 1.18
TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem (2004) 1.17
PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest (2002) 1.16
Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med (2010) 1.16
Growth hormone receptor regulates β cell hyperplasia and glucose-stimulated insulin secretion in obese mice. J Clin Invest (2011) 1.12
Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Endocrinology (2004) 1.10
Insulin, insulin resistance, obesity, and cancer. Curr Diab Rep (2010) 1.07
Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology (2008) 1.06
Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endocrinology (2003) 1.04
Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone (2008) 1.03
Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes (2013) 1.01
Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res (2008) 1.01
High-efficient FLPo deleter mice in C57BL/6J background. PLoS One (2009) 1.01
The metabolic syndrome--from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am (2008) 1.00
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00
A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab (2007) 0.99
Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes (2004) 0.98
Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer (2010) 0.98
Role of growth hormone (GH) in liver regeneration. Endocrinology (2004) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Determining mammosphere-forming potential: application of the limiting dilution analysis. J Mammary Gland Biol Neoplasia (2012) 0.97
Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signaling and gene expression. Recent Prog Horm Res (2003) 0.96
The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract (2011) 0.95
The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm (2013) 0.95
Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis. Biol Blood Marrow Transplant (2004) 0.95
Intracerebroventricular leptin infusion improves glucose homeostasis in lean type 2 diabetic MKR mice via hepatic vagal and non-vagal mechanisms. PLoS One (2011) 0.95
The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary alphaT3 cells by protein kinase Calpha-mediated negative regulation of Akt. J Biol Chem (2004) 0.93
Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc (2008) 0.93
Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol Endocrinol (2004) 0.92
Hyperinsulinemia and type 2 diabetes: impact on cancer. Cell Cycle (2010) 0.91
Effect of case-based training for medical residents on confidence, knowledge, and management of inpatient glycemia. Postgrad Med (2011) 0.91
Clinical relevance of systemic and local IGF-I. Endocr Dev (2005) 0.91
Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin Cornerstone (2004) 0.90
Insulin and IGFs in obesity-related breast cancer. J Mammary Gland Biol Neoplasia (2013) 0.89
Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med (2015) 0.89
Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner. Endocrinology (2008) 0.88
The role of insulin receptor signaling in zebrafish embryogenesis. Endocrinology (2008) 0.88
MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness. Am J Physiol Endocrinol Metab (2006) 0.88
Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes (2013) 0.87
The cyclin-dependent kinase inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells. J Biol Chem (2003) 0.86
Decreased IGF type 1 receptor signaling in mammary epithelium during pregnancy leads to reduced proliferation, alveolar differentiation, and expression of insulin receptor substrate (IRS)-1 and IRS-2. Endocrinology (2011) 0.86
Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model. Endocrinology (2013) 0.86
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract (2015) 0.85
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer (2009) 0.85
Impaired muscle regeneration and myoblast differentiation in mice with a muscle-specific KO of IGF-IR. J Cell Physiol (2010) 0.84
Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer (2013) 0.84
Is growth hormone resistance/IGF-1 reduction good for you? Cell Metab (2011) 0.83
Protection against hypoxic-ischemic injury in transgenic mice overexpressing Kir6.2 channel pore in forebrain. Mol Cell Neurosci (2004) 0.83
Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2014) 0.82
Insulin-like growth factor-I: compartmentalization within the somatotropic axis? News Physiol Sci (2002) 0.82
Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care (2015) 0.82
Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res (2012) 0.82
Skeletal muscle growth hormone receptor signaling regulates basal, but not fasting-induced, lipid oxidation. PLoS One (2012) 0.82
Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care (2014) 0.81
The GH/IGF-1 axis in growth and development: new insights derived from animal models. Adv Pediatr (2010) 0.81
Liver-specific IGF-I gene deficient mice exhibit accelerated diabetes in response to streptozotocin, associated with early onset of insulin resistance. Mol Cell Endocrinol (2003) 0.80
Diabetes cure--is the glass half full? N Engl J Med (2006) 0.80
14-3-3sigma mediation of cell cycle progression is p53-independent in response to insulin-like growth factor-I receptor activation. J Biol Chem (2004) 0.80
The WT1 Wilms' tumor suppressor gene: a novel target for insulin-like growth factor-I action. Endocrinology (2003) 0.80
Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort. BMC Cancer (2012) 0.80
Deletion of growth hormone receptors in postnatal skeletal muscle of male mice does not alter muscle mass and response to pathological injury. Endocrinology (2013) 0.79
Skeletal muscle. Adv Exp Med Biol (2005) 0.78
Building Momentum: Taking on the Real “Issues” of Diabetes Care! Diabetes Care (2016) 0.78
Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse. Novartis Found Symp (2004) 0.77
Regulation of the splenic somatotropic axis by dietary protein and insulin-like growth factor-I in the rat. Growth Horm IGF Res (2003) 0.77
Hodgkin lymphoma in temporal association with growth hormone replacement. Endocr J (2005) 0.76
Gender differences in metabolic disorders. Gend Med (2009) 0.76
Intensive insulin therapy in the medical ICU. N Engl J Med (2006) 0.75
Does a single nucleotide polymorphism in the FGFR explain the connection between diabetes and cancer? Cell Metab (2013) 0.75
IGF-I: panacea or poison? J Clin Endocrinol Metab (2010) 0.75